Login
Navigate Fool.com
Will GSK beat
the market?

GlaxoSmithKline

NYSE: GSK

Community Rating: 3 Stars: Appealing

52.51 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $52.34
Previous Close $52.51
Daily Range $52.28 - $52.75
52-Week Range $48.30 - $56.73
Market Cap $127.5B
P/E Ratio 18.15
Dividend (Yield) $3.00 (4.7%)
Ex-Dividend Date
Dividend Pay Date
02/19/14
04/10/14
Volume 2,219,393
Average Daily Volume 2,308,660
Current FY EPS $3.61

How do you think GSK
will perform against the market?

Top GSK Bull/Bear Pitches

 

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!

 

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary Rss Feed

Is Johnson & Johnson's Dividend Unbeatable?

Johnson & Johnson sports a solid dividend, but is it the right pick for your portfolio?

Pharmaceutical Stocks For Income, Value And Growth Investors

Down 17%: Is Isis Pharmaceuticals Worth Buying Now?

Despite a deep product pipeline of intriguing RNAi drugs, shares in Isis (ISIS) have toppled this year. Here's what you need to know about Isis and the catalysts likely to move its shares in the coming year.

Why Investors Need to Watch Sarepta Therapeutics Inc.

The FDA will soon decide the path forward for Sarepta's muscular dystrophy drug.

Tuesday’s Top Health Care Stories: Johnson & Johnson, Teva, Mylan, and Dynavax

Johnson & Johnson, Teva, Mylan, and Dynavax could all loom large in health care headlines this Tuesday morning.

The Supreme Court Will Decide the Fate of a Blockbuster

Teva's day in court is coming.

Impax Breathes New Life Into Stalled Parkinson's Drug

Impax's (IPXL) stumbles in bringing Rytary, it's long lasting Parkinson's drug, to market may finally be over given its re-filed with the FDA for approval.

More Trouble Looming for Amarin Corporation?

Teva announced yesterday that it's launching a generic version of GlaxoSmithKline's Lovaza. Will this launch hurt Amarin's competing product?

Biotech Stocks to Watch as Sector Sells Off

Some companies are short on cash levels and could have difficulty issuing shares.

The Worst Biotech Failures of the Week

See which companies suffered the worst clinical setbacks in the week ending April 4.

See More GSK News...

Sector

Healthcare

Industry

Drugs

GlaxoSmithKline (GSK) Description

The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products. Website: http://www.gsk.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks